## VCYT: Veracyte, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.78 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-8.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($40.21)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Capital Fund Management S.A. Takes Position in Veracyte, Inc. $VCYT**
- Source: MarketBeat | 20251205T045137 | Bullish | Relevance: 100%
- Capital Fund Management S.A. acquired a new position in Veracyte (NASDAQ:VCYT) during the second quarter, purchasing 73,702 shares valued at approximately $1.99 million. This makes up about 0.09% of the company's stock. Despite insider selling, Veracyte exceeded recent quarterly expectations with strong EPS and revenue growth, leading analysts to maintain a "Moderate Buy" rating with a consensus price target of $44.38.

**2. Annie Mcguire, Veracyte SVP, sold $67k in VCYT stock**
- Source: Investing.com | 20251205T180910 | Neutral | Relevance: 100%
- Annie McGuire, SVP and General Counsel of Veracyte Inc. (NASDAQ:VCYT), sold 1,422 shares of common stock for $67,260 on December 4, 2025, and disposed of 3,052 shares for $140,880 on December 2, 2025, to cover tax obligations. Following these transactions, McGuire directly owns 78,499 shares. This news follows Veracyte's strong Q3 2025 earnings report, which exceeded analyst expectations and led to raised guidance and increased price targets from Needham and Canaccord Genuity.

**3. Veracyte NASDAQ:VCYT CEO Stapley sells $361k in shares**
- Source: Investing.com | 20251205T045138 | Neutral | Relevance: 100%
- Veracyte CEO Marc Stapley sold $361,075 worth of company stock on December 4, 2025, involving 7,668 shares priced between $46.9005 and $47.3485. These transactions, executed under a pre-arranged trading plan, occurred near the stock's 52-week high after a significant 77% price surge. Separately, 7,914 shares were disposed of to cover tax obligations from vested restricted stock units, and the company recently reported strong Q3 2025 earnings and raised its guidance.

**4. Panagora Asset Management Inc. Sells 41,108 Shares of Veracyte, Inc. $VCYT**
- Source: MarketBeat | 20251205T045137 | Somewhat-Bullish | Relevance: 100%
- Panagora Asset Management Inc. reduced its stake in Veracyte, Inc. by 19.7% in Q2, selling 41,108 shares and holding 167,076 shares valued at $4.52 million. This comes as company insiders also sold 90,882 shares worth $3.88 million, although insiders still own 1.40% of the stock. Veracyte recently exceeded quarterly earnings estimates, and analysts currently maintain a "Moderate Buy" rating with an average target price of $44.38.

**5. Veracyte VCYT: chief commercial officer Leite sells $61k in stock**
- Source: Investing.com | 20251205T045137 | Neutral | Relevance: 100%
- John Leite, Chief Commercial Officer-CLIA at Veracyte (NASDAQ:VCYT), sold 1,278 shares of common stock for $60,717 on December 4, 2025, under a Rule 10b5-1 plan. This transaction, along with shares withheld for tax obligations, occurred while Veracyte recently exceeded Q3 2025 earnings and revenue expectations, leading to raised guidance and increased price targets from Needham and Canaccord Genuity.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $48 | $40 | +20% |
| 2025-11-11 | Morgan Stanley | $40 | $28 | +43% |
| 2025-11-05 | UBS | $48 | $42 | +14% |
| 2025-11-05 | Canaccord Genui | $43 | $40 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |
| 2025-11-11 | Morgan Stanley | main | Underweight |
| 2025-11-05 | UBS | main | Buy |
| 2025-11-05 | Canaccord Genui | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 25 ($5.77M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 16.5% (+68.9%)
- Vanguard Group Inc: 10.8% (+5.0%)
- Artisan Partners Lim: 9.3% (+16.6%)
- FMR, LLC: 8.6% (-16.2%)
- ARK Investment Manag: 5.7% (+17.5%)

### Key Risks

1. High beta (1.83) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_20 falling (-8.4% 5d) with bearish MACD, trend may be turning.
3. Insider selling cluster: $5.8M in recent transactions.

### Catalysts

- Analyst target momentum: 6 raises (avg +17%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.78 indicates undervaluation relative to growth. Balance sheet: strong liquidity (6.2x), low leverage (D/E 0.09). Analyst sentiment positive (6 raises, avg +17%). Insider selling cluster ($5.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.4B |
| Beta | 1.83 |
| 52W Range | $22.61 - $50.71 |
| Short Interest | 7.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.78 |
| Forward P/E | 27.8 |
| Current P/E | 27.1 |
| YoY Growth | -2.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 8.2% to -0.2% (-8.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.2pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 55. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.24% (CS: 51) | Neutral |
| RSI_14 | 55.2 | Neutral |
| MACD Histogram | -0.03 | Bearish |
| vs SMA20 | 1.020x | Above |
| vs SMA50 | 1.143x | Above |
| vs SMA200 | 1.402x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $44.61
- **Stop Loss:** $40.21 (9.9% risk)
- **Target:** $53.41 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 113
- **Position Value:** $5,040.93
- **Portfolio %:** 5.04%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-24 (Est: $0.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.32 | $0.51 | +59.5% |
| 2025Q2 | $0.30 | $0.44 | +48.5% |
| 2025Q1 | $0.20 | $0.31 | +51.3% |
| 2024Q4 | $0.26 | $0.36 | +40.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*